Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

WAY-169916

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Synthesis of 1H-indazoles from N-tosylhydrazones and nitroaromatic compounds.
A new method for the synthesis of 1H-indazoles from readily available N-tosylhydrazones and nitroaromatic compounds has been… Expand
  • figure 1
2012
2012
Characterization of agonist binding to His524 in the estrogen receptor α ligand binding domain.
The bioactivities of the natural steroidal estrogen 17β-estradiol (E2), the synthetic estrogen diethylstilbestrol (DES), and the… Expand
Highly Cited
2010
Highly Cited
2010
Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity
The concept of selective receptor modulators has been established for the nuclear steroid hormone receptors. Such selective… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates the toxicity of 2,3,7,8… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
2007
2007
The Pathway-Selective Estrogen Receptor Ligand WAY-169916 Reduces Infarct Size After Myocardial Ischemia and Reperfusion by an Estrogen Receptor Dependent Mechanism
Previous studies have shown that estrogen treatment protects the heart from reperfusion injury. The adverse effects of long-term… Expand
2006
2006
The Pathway-selective Estrogen Receptor Ligand WAY-169916 Displays Differential Activity in Ischemia-Reperfusion Injury Models
We previously reported on the development of a pathway-selective estrogen receptor (ER) ligand, WAY-169916, that has ER-dependent… Expand
2005
2005
Nuclear receptors: Choosing the right path
  • J. Owens
  • Nature Reviews Drug Discovery
  • 2005
    • Corpus ID: 38990431
A compound that acts via the oestrogen receptor (ER) to selectively inhibit nuclear factor-κB (NF-κB) without displaying… Expand
2005
2005
Screening: Hitting the hot spots
A compound that acts via the oestrogen receptor (ER) to selectively inhibit nuclear factor-κB (NF-κB) without displaying… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE